<SEC-DOCUMENT>0001178913-15-000031.txt : 20150107
<SEC-HEADER>0001178913-15-000031.hdr.sgml : 20150107
<ACCEPTANCE-DATETIME>20150107065533
ACCESSION NUMBER:		0001178913-15-000031
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20150107
FILED AS OF DATE:		20150107
DATE AS OF CHANGE:		20150107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAMADA LTD
		CENTRAL INDEX KEY:			0001567529
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35948
		FILM NUMBER:		15512052

	BUSINESS ADDRESS:	
		STREET 1:		7 SAPIR ST. WEIZMANN SCIENCE PARK
		CITY:			NESS ZIONA
		STATE:			L3
		ZIP:			74140
		BUSINESS PHONE:		97289406472

	MAIL ADDRESS:	
		STREET 1:		7 SAPIR ST. WEIZMANN SCIENCE PARK
		CITY:			NESS ZIONA
		STATE:			L3
		ZIP:			74140
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk1516038.htm
<DESCRIPTION>6-K
<TEXT>
<html>
<head>
    <title>zk1516038.htm</title>
    <!--Licensed to: ZKG-->
    <!--Document Created using EDGARizer 2020 5.5.0.0-->
    <!--Copyright 1995 - 2014 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">UNITED STATES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 14pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Washington, D.C. 20549</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 14pt; FONT-WEIGHT: bold">FORM 6-K</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Report of Foreign Private Issuer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Pursuant to Rule 13a-16 or 15d-16</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">of the Securities Exchange Act of 1934</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the Month of January, 2015</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Commission File Number 001-35948</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 16pt; FONT-WEIGHT: bold">Kamada Ltd.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Translation of registrant&#8217;s name into English)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">7 Sapir St.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Kiryat Weizmann Science Park</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">P.O Box 4081</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Ness Ziona 74140</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Israel</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;(Address of principal executive offices)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Form 20-F <font style="DISPLAY: inline;" face="Wingdings 2, serif">T</font>&#160;&#160;&#160;Form 40-F <font style="DISPLAY: inline;" face="Wingdings">&#168;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Yes <font style="DISPLAY: inline;" face="Wingdings">&#168;</font>&#160;&#160;&#160;No <font style="DISPLAY: inline;" face="Wingdings 2, serif">T</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If &#8220;Yes&#8221; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-____</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">This Form 6-K is being incorporated by reference into the Registrant&#8217;s Form S-8 Registration Statement File No. 333-192720.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following exhibit is attached:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">99.1</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">News Release: Kamada Reports Encouraging Discussions with European Co-Rapporteurs Regarding&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">European Filing for Inhaled Alpha-1 Antitrypsin to Treat AATD and expects to report results from its Anti-Rabies Immunoglobulin U.S. Phase II/III clinical trial in the first half of 2015.</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURE</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -9pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -9pt" align="left">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Date: January 7, 2015</font></div>
</td>
<td align="left" valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">KAMADA LTD.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">By:&#160;&#160;<font style="DISPLAY: inline">/s/ Gil Efron</font></font></div>
</td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Gil Efron</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Chief Financial Officer</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">EXHIBIT INDEX</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline"><font style="DISPLAY: inline">EXHIBIT NO.</font></font></div>
</td>
<td valign="top" width="75%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline"><font style="DISPLAY: inline">DESCRIPTION</font></font></div>
</td>
</tr><tr>
<td valign="top" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="75%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="8%" style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">99.1</font></div>
</td>
<td valign="top" width="75%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">News Release: Kamada Reports Encouraging Discussions with European Co-Rapporteurs Regarding</font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> European Filing for Inhaled Alpha-1 Antitrypsin to Treat AATD and expects to report results from its Anti-Rabies Immunoglobulin U.S. Phase II/III clinical trial in the first half of 2015.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit_99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
<head>
    <title>exhibit_99-1.htm</title>
    <!--Licensed to: ZKG-->
    <!--Document Created using EDGARizer 2020 5.5.0.0-->
    <!--Copyright 1995 - 2014 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block"><font style="FONT-WEIGHT: bold; TEXT-DECORATION: underline">Exhibit 99.1</font><br>
</div>



<div>&#160;</div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">News Release</font></font></div>
</td>
<td width="50%" style="TEXT-ALIGN: right"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;<img src="img1.jpg" alt=""></font></td>
</tr></table>
</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Kamada Reports Encouraging Discussions with European Co-Rapporteurs </font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Regarding European Filing for Inhaled Alpha-1 Antitrypsin to Treat AATD</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Expects to report results from its Anti-Rabies Immunoglobulin U.S. Phase II/III clinical trial in the </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">first half of 2015</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">NESS ZIONA, Israel (January 7, 2015) &#8211; Kamada Ltd. (NASDAQ and TASE: KMDA), </font>a plasma-derived protein therapeutics company focused on orphan indications, today provides a clinical/regulatory update.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Kamada has held encouraging pre-submission meetings with its European rapporteur and co-rapporteur with regard to the Company&#8217;s Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for its inhaled alpha-1 antitrypsin (AAT) for the treatment of alpha-1 antitrypsin deficiency (AATD).&#160;&#160;The co-rapporteurs advised that they would consider the entire study data once submitted, including post hoc analysis and will not reject the application simply because the primary endpoint of the study was not met. They agreed that the application fulfills the requirements relating to unmet medical need and benefit to public health and that it may meet the scope of Conditional Approval (CA) if the company convincingly proves the positive benefit-risk balance of the product, by the time of MAA filing.&#160;&#160;The co-rapporteurs have requested the addition of supplemental data analyses that may address the benefit<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">-</font>risk balance and support the already available safety and efficacy data.&#160;&#160;Kamada has begun conducting the additional data analyses and plans to file the MAA with the EMA in Q4 2015.&#160;&#160;In addition, the Company expects to present the complete data set from the Phase II/III clinical study at the upcoming American Thoracic Society Annual Meeting in May 2015.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Kamada expects to report results from its anti-rabies immunoglobulin<font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font>U.S. Phase II/III clinical trial as a post-exposure prophylaxis for rabies in the first half of 2015 and maintains plans to file a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) in 2015. Kamada has a strategic agreement with Kedrion S.p.A for the clinical development and marketing of the product in the U.S.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;We are particularly pleased with our constructive dialogue with the co-rapporteurs regarding our plans to file for approval with the EMA for our inhaled AAT as a treatment for AATD,&#8221; said David Tsur, co-founder and Chief Executive Officer of Kamada.&#160;&#160;&#8220;We remain steadfast in our belief that the clinically efficacious differences seen in lung function parameters in our European Phase II/III clinical study are therapeutically relevant.&#160;&#160;Consequently, we continue to work closely with the European regulatory authorities toward a path to bring this therapy to patients suffering with AATD with a regulatory filing in towards the end of this year.&#8221;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About Kamada</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Kamada Ltd. is focused on plasma-derived protein therapeutics for orphan indications, and has a commercial product portfolio and a robust late-stage product pipeline.&#160;&#160;The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived proteins.&#160;&#160;&#160;AAT is a protein derived from human plasma with known and newly-discovered therapeutic roles given its immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties. The Company&#8217;s flagship product is Glassia&#174;, the first and only liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. Food and Drug Administration. Kamada markets Glassia in the U.S. through a strategic partnership with Baxter International.&#160;&#160;In addition to Glassia, Kamada has a product line of nine other injectable pharmaceutical products that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, India and other countries in Latin America, Eastern Europe and Asia.&#160;&#160;Kamada has five late-stage plasma-derived protein products in development, including an inhaled formulation of AAT for the treatment of AAT deficiency that completed pivotal Phase II/III clinical trials in Europe and entered Phase II clinical trials in the U.S.&#160;&#160;&#160;Kamada also leverages its expertise and presence in the plasma-derived protein therapeutics market by distributing 10 complementary products in Israel that are manufactured by third parties.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cautionary Note Regarding Forward-Looking Statements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This release includes forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995.&#160;&#160;Forward-looking statements are statements that are not historical facts, such as statements regarding assumptions and results related to financial results forecast, commercial results, timing and results of clinical trials and EMA and U.S. FDA authorizations.&#160;&#160;Forward-looking statements are based on Kamada&#8217;s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions.&#160;&#160;Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, unexpected results of clinical trials, delays or denial in the U.S. FDA or the EMA approval process, additional competition in the AATD market or further regulatory delays.&#160;&#160;The forward-looking statements made herein speak only as of the date of this announcement and Kamada undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">.</font></font></div>

<div>&#160;</div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="50%"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> </font>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Contacts:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Gil Efron</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">CFO</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">ir@kamada.com</font></font></div>
</td>
<td width="50%">
<div><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Anne Marie Fields</font></div>

<div>LHA</div>

<div>212-838-3777</div>

<div><font style="DISPLAY: inline; TEXT-DECORATION: underline">afields@lhai.com</font></div>
</td>
</tr></table>
</div>

<div>&#160;</div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img1.jpg
<TEXT>
begin 644 img1.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``34T`*@````@`!`$:``4`
M```!````/@$;``4````!````1@$H``,````!``(```$Q``(````0````3@``
M``````!@`````0```&`````!4&%I;G0N3D54('8U+C`P`/_;`$,``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_``!$(`$D!
M`@,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`/[OM9UG4K34KFWM[GRX8_)V)Y,#8W01.WS/$S'+,QY8XS@<8%9?
M_"0ZQ_S^?^2]K_\`&*/$/_(8O/\`MW_])8*Q:`-K_A(=8_Y_/_)>U_\`C%'_
M``D.L?\`/Y_Y+VO_`,8K%_SSP/J2>`/4G@5\%_M*?\%#?@1^SM//X>?5!X\\
M>QHP/A/PQ-'<M8S9PL>KZCG['I\O1_)ED\QD((Y(%>ODN0YSQ'CH9;DF78K,
ML;4U5'"TW-PA>SJ59Z4Z-*-_>JU9PIQZR1X^><09+PU@*F9Y]F6$RO`T]'7Q
M5504Y6NJ=&&M2O5DE[M*C"=27V8L_0[_`(2'6/\`G\_\E[7_`.,4?\)#K'_/
MY_Y+VO\`\8K^=ZV_X*'_`+8/QSOK^+X+?#]K&SL'C\Y/"NBIX@U&TAGWFW_M
M`W:2PK+(JG_5`JQ1MO`KIM!_:2_;XN=,N=;O1XJ?1]-DNEU+47\%Z1'96IL)
M'BOH[B86@$9MI(WCN,9,;*0<&OTY^"'%-&-L=FO"N78E.G&I@<5G2^MTIU5S
M4H584,/6A&=5?PX^T;G9N-UJ?C-7Z1?!O-S8#(^-LVPC]JZ>8X#AZ^#K1H-*
MO.C4Q&,P\YPHM_O9>S2IZ<_*W8_?O_A(=8_Y_/\`R7M?_C%'_"0ZQ_S^?^2]
MK_\`&*_%SP1_P4,\?Z5-'#XX\/:=XDLLH)KBRVV.I\<.4_U=KR,M@C[W3BOT
MB^$?QZ^'?QFTX7/A75D34XXU>]T"_P`6VJVA(YQ`Y!N(E/'G0[E)]N:^1XD\
M/.*^%J;Q&99<YX)-)X[!5%BL+&]K.K*"52@FW9.M3IQ;T3;/LN#?%W@3CFK'
M"9-FZI9E)7CE>94W@<=.RNU0A4;HXEQ5VXX:M6DDKM):GT#_`,)#K'_/Y_Y+
MVO\`\8H_X2'6/^?S_P`E[7_XQ6+2$@=2!V^8@<^F21S[5\0?IAM_\)#K'_/Y
M_P"2]K_\8H_X2'6/^?S_`,E[7_XQ6)N7^\G_`'VO^-.`).`,GT')/T'4^^.E
M`&S_`,)#K'_/Y_Y+VO\`\8H_X2'6/^?S_P`E[7_XQ6,00=IX;KM/#8]=O7'O
MC%(3CDX`'))X`'J2>`/<T`;7_"0ZQ_S^?^2]K_\`&*/^$AUC_G\_\E[7_P",
M5A))'*N^*6*9,D!X9$E0D=0'C9E)'0C.0>#@T_-&NUM=K!<VO^$AUC_G\_\`
M)>U_^,4?\)#K'_/Y_P"2]K_\8K$RIZ,I^C*3^0.:6@#:_P"$AUC_`)_/_)>U
M_P#C%'_"0ZQ_S^?^2]K_`/&*Q:3*CJRCV+*#^1.:`-O_`(2'6/\`G\_\E[7_
M`.,4?\)#K'_/Y_Y+VO\`\8K%IDDL42[YI8H4R%WS2)$FYCA5WR,J[F/"KG<Q
MX`)H"]M7HC=_X2'6/^?S_P`E[7_XQ1_PD.L?\_G_`)+VO_QBL7-(2!U*C/3<
MP7/TR1F@#;_X2'6/^?S_`,E[7_XQ1_PD.L?\_G_DO:__`!BL4$$X#*2>@#*2
M?H`<D_2G%67[RL/J"/YT7`V/^$AUC_G\_P#)>U_^,4?\)#K'_/Y_Y+VO_P`8
MK%HH`VO^$AUC_G\_\E[7_P",4?\`"0ZQ_P`_G_DO:_\`QBL(2Q,[QK+$TL>/
M,B26-I8MWW?-B5B\>[^'>J[NV:?0%S:_X2'6/^?S_P`E[7_XQ1_PD.L?\_G_
M`)+VO_QBL6B@#VBBBB@#S'Q#_P`AB\_[=_\`TE@K%K:\0_\`(8O/^W?_`-)8
M*\*^/'Q1L/@K\'?B'\4M2>)(?!WAO4-3@$QQ%+J*0.-.MWR0-L]WY<1YS\W`
M-=&$PM?'8O#8+"TW5Q.,Q%'"X>G'>I7Q%2-*E!><ISC%>IS8S%X?`83%8[%U
M%1PN"P];%8FK+:G0P].56M4?E"G"4OD?DG_P59_X*+7GP1A?]GCX-ZG#%\2]
M>M,>-/$=NZRW/@S2+A`PL;,*2L&LWR,H,K_O;6$Y5/WF:_G-T"_OM4NI=2U.
M\N=0U&^F-S>7UY,]Q=74\CAGEFFD+/([,2<D\=!@<5Y+XX\?^(OBG\0O$GQ$
M\67L^H>(/%^MWFMZA<7$C2R*][.TT=L'8DF*TB9+:$'I'$HKT_PC_JXO^`_^
MA+7^H/`OA[E?AUPOA<JPE*E4S*M2I5LZS)07ML=CY<CJ?O'[ZPM"3=+"T;J,
M*45-IU9U)R_RIXZ\2,V\2N*\=F^,JU8971G4HY%ECD_8Y?EZE:E^[7NO%UXV
MJXNM;FG4DX)JE"G"/Z(_L;>)_&&@?&SP';^$Y]?E-_KMH;[1-!N?(EUF&W1W
M,,B,5BD$<?F-^^8(J[B2!S7ZS^,]%^,GQ@^&6DV'PM\,^([6QMOB1\1IM?F.
MM:98V6HVMYJ^IQ?8''VM?M)MKC=',,&,M&SH2N"?SH_8GTV/P?HGQ;^/^H@+
M;_#WPJ=#\.JRXFN/%WB</;V!LR?ORP6L%XS*F'Y!%?=7P_N?#)_9W_9^U;XF
M>*-<\/Z):^(/B%K>K0:7-<6NH>)-2B-[=0:22DD1S?7;8<R9"AF;&<U^,<?U
M5/B6GF.!PF$J8C+,;EV5JK4P.(S"6(S!Y1G6:U:7U+#8C"O%U*&%J8*E04JB
M]G5Q2;DHTK+](X`I<O"6)RG,L=C:6$SG+\US>5&EF6%RJ&&RQ9]PWDU&M_:6
M,PF.C@:6(QE''UL0XT7[2A@W&%-RKMR^:_'WP?\`B1\,/LK>./"]]HL5[_QZ
MW3[+BRF;KL2\MS);F3'.SS-Y'.*Y+PUXGU[PAK%EK_AS4[K2=5L)DFM[JUE:
M-@R'.V100LL;<AD<%2">AYK[YA^,NH?'KP+\:=&U73+>Q\$^$_"%M=^#M"8_
M:9]*DL9-MO=R7KCS'O)0H:=QMW<J>*_.=3E5/J`?TKV^',QS+-\+C\#Q'@,'
M0S'!U*6'QV'H/VV$JTL9A*6*I*5.K*JHU/95O9XFC[2O252,N2M4@[K\YXPR
MC)\@Q^59EPAFF8XK*,QI5L7EF+Q<?J^84,1EV.K8&O*-2C"@Y4WB,/[?!8GV
M&%K2I3BZF'HU(M/]]?V7_P!H:R^.'A4PZ@8;3QKH,,4.NV2$*MVH`1-4MHR<
MB*X.UI5&1%,S(/E%>K_%KX=V'Q-\'7N@:AKWBKPX(1-?VFJ>#];ET+58+R&W
MD$#/=11RF:V1CN>U==DI&"1UK\(/V?/B9?\`PL^*?ACQ!;3F*PN-0MM+UQ,D
M)+I-_*MO=;QT8Q)(9(\]'`(P:_H:N)X[K1Y[F%@T5SILD\3#D&.:U,B'(XY5
MATK^7/$GA5\#\583&9.Y8;`X^?UW+7#5X/$4JD5B,/#F37)2E.$Z2ES?NJJ@
M[J.O]Q^#'':\3.!\;E_$"CB\URF*RS..?W5F&$JTG+!XVHHN+]I6C3J4\1*/
M+>O0E433G9?@S_P3ITCQM\;OC'\:K#XB_&/XK:QI7P;U*T_L+3H/%4UE!J<[
M:]J&F1OJVR!S<PK%:*SVWRK(7(+``5]D_MC>(?$GQ(\<^$O@3^S_`.+?'&C_
M`!P5[6?4]>\):Y-9>&_`?AMY%N;_`%#Q?!';SVMS>W.GB5;."ZEB?,D)16DP
M*_';X$?M0:S^S+K'[7&H^'-&O;O7?&GB>TT"RU]+8SZ7X43_`(2W6C=:MJ`4
MJ7G2&1FT^VW)]HG1E\Q-N:_?S]C#PO\`##3_`(2V'C3X?^*'^(&J^/BVO>,_
M'VH*HUW6O$%TWFW]I?QEYI["'3[@M;6VFO-(EO%$BJS@!J_4O%+!XKA;B>KQ
MSBL#"IEU"AE>7<)9;2P=%95/,JV09?B,QQ6:0HT?JT<%3Q%:M4>`K\M?-J_-
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M\*O&.I7=YXN^'GB:]N#_`&I)++JD]GJDAEN1*\[-*R65TKPG=@*3QP0*_6B_
MLX]1LKJPEDGABO();>26UE,%S&DJE&>"903%*H.4<`E6P<5^`.D:SIG[*/\`
MP4YN3I6KZ;=?#WXUW%M]LETR\MKFR@_X2SYH;&'[--)$DMIJYMXV9R&Q(V!W
M/]!/3T/N.1^!%?2>,66T*'%&$XGRVC]7ROC7*L!Q/@H1AR1P^)Q5*"S'"J/+
M%1J8?&PG.<++E]M&Z2:1\EX!9MB<1P9C>#LXQ'UK.O#S.\RX-S&<YJI/$X/!
MU92RC&.7-)SIXK+:E.$*G-)3]A/WI--O^<W]KGQQ\1OV-_VJ_!)\'?%;XB:W
M\/U;1O$FI>&?$/B*375337NH(=6T^\DDA1C%=++)]F\P*8P5$><`G^@KP3XM
MTGQYX0\-^,]"N8KO2/$VCV>KV-Q"P>-X[J(,ZJRY!\J820MCHR$5^7_[1?P,
MTC]HWXR_M.>"/LW_`!4^F?!/PS<^';HHK,NKV-[I>LV5O"Q&8EO7@%I<2`Y\
MJ1Q@C@\A_P`$E_CI?W_AOQ?^SCXTNFC\3?#;4+J?P_;73'SY-),S0ZA8QAR"
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M74>6QPU?I_\`M/W=W\8?B;\,?V7-"ED;3=7OX_'GQ;F@)"67@S0I$;3M-GD3
M.V36M0:2+R9,!D@S@]OA[]DZQT7PW_P4Y_:$T?38H-.M&B\10V-I&-B.Z7<3
M%8HU^53Y<9<JH"@`X`K'P]P.$RC@7CO&3P\)<28[@^MG>7XF5*E5JY3E6'S&
MA@</4I*K"<J&)S&K/%XA58*,X87#8:K&2C64C?Q3S''Y]XE^&F`ABJE/A#+>
M/<+P[FF%A7K4:.>9WBLJK9EBZ59T:E..(PF4T(X'"2HU'.$\;C,71G!SP[B?
MN7:VZV=K;6D;RR):P16Z23R&6>188UC5YI3@R2L%!D<@%VRQ&37XF_\`!6GX
MG>/].F\$^&/A_JFO6>G^"18>/_'SZ+<S06\%K/J4>EZ$FK&##;6U%U,$;NJE
MCE@PXK]M9IX+6&:ZN7$5M;127%S*>D<$*&2:0^R1JS'Z5^6_@'2O!?[1WA']
MK'QEXGU_P]N^+6I:OX+\'?VEJ^F6_P!G\.>#WN(-(N8H)[D2IYNH6<-[&VT#
M>P9<G!/Q/A9B</DV?/B_,L&L?E^0UL#3J4)TO:QJXG.<7'`_#RR3J8?`/,L?
M3NM)X2+ML?HOC1A,7Q!PRN!,HS!Y9FG$U#,:U'$4ZRH3HX/(,$\Q=Y<\)*EB
MLS_LC+*B3M*ECJB/N;]GGXG6/QA^"OPX^(5C-%*VO^%M+DOXXGW_`&74K>W6
MUO+:4\D3+)#OD#?,#)S6+^TE\/+;QW\-M;N#XG\8^%-2\,:1K.K:/J7@_7IM
M$F%Z+,,O]H+''(M_;IY"E()-JJ6<Y.ZOS/\`^"0_Q0NK&U^*G[.6NW8DOO!&
MOZEK/AZ/S5F5[!KHPZH8Y0Q5HQ,(FA6,E=CDCTK]<?BK_P`DU\=?]BMK7_I#
M-6/%>15^!_$K%9;A)NG2P^<4,5E=9)253*\QJ0Q&#DE-2C.#PE=4)J2E&3C4
MC*^IT<#\2X?Q'\(L#F^/IQK5L7D&(P6=8>3E&5/.<JISPN81FZ<H3IU(X["O
M$TW&4914Z4XVNC\7/^":_A3Q#^TSX(^)WB#XF_&#XSRZWX3\5:?I&@7FA>/;
MK1X[6"YL+B<O/:QVDL=U(LT2.#(1QE>AS7TM\6_A7^V)^SUIU[\2_@E\:_$7
MQBT304?4]<^'/Q'MK;6-0GTNU#37:Z7J$:PS2O\`9U=FRF^,)O1217C_`/P1
M4_Y)E\</^R@:-_Z:[ROVLVH_R2()(Y`8Y(V&5DC<;9(V!X*R(61E/!4D'@U]
MIXG<5XSAWQ2XGP-/!Y5F&187'8.F\@S#*\!B,NGA9Y;@:M;#T8RH>UP7M95*
MDE6P=6A5A4G[12OO^>>#7!6`XL\%^#LQK8_.\LXDQF7XZK'B;*\YS+"YM#&P
MS;,:6'Q5><<5[',/8PITH.ACZ.(HSHP5)P4=5\A?L@?M<^$_VK?!-WJMA9CP
M]XT\.2QVGB[PE-.))["=E^6\M@^)WL)I`T:22(,2*8\[@0/J7Q%K=GX:\/ZY
MXBU%Q'8:#I&HZQ>.2`%MM.M);J8Y/'W(CC^O2OY__P!G-9_@[_P5.\>^!/#C
M"+P_XGE\1#4K"W.R!X[E%U2T38@VA+*>XD,<>,+G`V]OU%_;@\>#1/AQH7PV
MLKNWMM<^,OB_0O`T$DUW':"UT6>^BN_$5[+)(RJ+?^QK2^MV)=5+2A2W->'Q
MGP'E^$X[R++<A52ED?%F793Q#@:-2<JM3+<LS"G*OC:52K)N<X8"G1Q-6%2;
MYWAXPYFYIM_2>'WB;FF.\->),WXG=&MQ)P1FN><+9E7I4X4:.;YOE56&&RZM
M2HPM"G4S2KB<'1G2@E!8J=3E48-)?F1^PQ\?_'ME^VMXW\/_`!,UC7;JT^-)
MNYO#*ZS<32*]O'>7<WA1=/AE*Q);R6<PC0P(-XCY9MI`_H*K\"/^"E'AG0?A
M'XB_9U^/7PQUK0I=5\`QZ-X4U!M&U*REFAM/#C02:9,T-C.[LUPL]VC/M!P!
MN9@:_;_X:>-K#XC_``_\'^.],P++Q7X?TS6H$#!C$+ZUCF,+E>/,C+;7'9N*
M[/%S#X3.,#PAQ_E6`CE^`SW+9Y+C,)3IJE'"9GP]/ZG&$H*$.7V^`6'G3]U<
MT:3EHG$X/`K%X[(,QX[\+\ZS.6:YEPUFU/B'`8^I5]M+'9-Q33CCYU(U'.HY
M?5LSEBH55SRY9UU&]U([BBBBOQ$_HL]HHHHH`\Q\0_\`(8O/^W?_`-)8*_'W
M_@M)XINO#W[%.M:9;O,D?C#Q7I6@W8B8*K01QR7X6;D%H_,@7A><U^P7B'_D
M,7G_`&[_`/I+!7X__P#!:+PG?>)?V*]9U*T5VC\'>*]*U^]"(6)MI(Y+#G&<
M`/,I)P?PK]`\*?J__$2>"/K7+['_`%CRV_-\/M/;+ZO\_K'LK>=C\Z\7'B/^
M(8<=_5>;VW^K696Y/B]G[%^W^7L/:<W]VY_&_9?\?,7^\/YU]`^$CB.+_@/\
MUKY^LO\`CYB_WA_,5]U_LE?#*;XO_&+X>>`DC#V>KZ]8R:T6SMAT"RGBNM:N
M&(!`$&GQS2$G"C;RP'-?ZA\08RAE^78O'XF7)A\%A:V*KS?V:6'C[6H_7EB[
M>9_E/PS@L1F698?+\)#VF*QU>AA,/#7WJV(JPI4UZ.<E?LC]Z_AIX*^'_P"S
M]^P_X!\9_$GP]=>);R7Q';>.IO!T<0(N_$.IV=Q'X<7Q2B_.NDV,,-W)%'=_
MZ,YG)"EPF*E[XB^&'C/]G/X.>)OBS!KFDPZ[XY\<:CI5GX/B@^S6,UU=7\TU
ML\<@!%I;P.(K<1@,`@KS_P"&/Q<L/C[\7?VD_@G/<%_"/CCPPVE_#ZTD(8P7
MO@$/!HMG8(3MCFN5DNV<Q*"RXR#WYSQMI]YI7[)G[/&FW\+07NG^-?'MC=Q,
M"#'=6<U];W$?(Y\N:-T..ZD=:_C^AE>(EF]*&<5\=A\^S'BO"YO*M0Q4Z4\-
MEF></9UCZ&'P=.2E3HSPN+IXO`XJIR3J5?JM-2DH<E.']59SG.&CD.,JY%A,
MNQ7#65<%XW(XT,3@X5J>,S?A_BOAS+L1B<?5BX5<1#&8*M@\QP=)U*=.A];J
M<E-S]I4G[EKE]\.]%_9T\7:C\"[/4XTUGQ'9^'_'VHZ[*\FL0::8%FLA`"S+
M:6ET<*Z1[/,R=P)-?"=?3G[-MQ%X@N/''PDO74VGQ'\.W46FQN!@>)=,@DN=
M+D!)`#2/''`!U8M@9Z5\V7MG<:=>7>GW:E+JQN9[.X4@C;/;2-#*,'GAT:ON
M.',/'+<?G^5SJU\1B5C*&91Q>+JRKXO%X+&X:G2H2K5I6E4>&K83$X."24:=
M*C2BDKL_&.,,7/.<KX5SRE0PV$PDLOQ633P&`H1PV7X#,<LQDZV)AAL/!M4E
MC</C\'F%2[E.I7Q%>3D[)*NK;&5^GELLF?38P;^E?T=_"35Y-?\`@KX+UF1S
M*]_X,BF9R&!.R">')#?-QY6,GTSTK^<15WLD>,^8ZQ@>I=@H_G7]`>C?#3Q#
MKOP!\`^!M&\8:K\/[RW\/64-[J>E013WK6DT$QELU$Y"Q[_/#B3!8''&*_,O
M':&$J8+A:GB,13PDI9MB$\34A4J1HX;ZO%UJCIT83K3BI^QO&G%MMQO;1G[9
M]%NICJ.9\;U<+A*N-A#(,(_JE*I2I3KXOZZUA:<:N(G3P].4J;Q5I5:D4HJ5
MGNG^1/\`P3>^&GA'XN^,_P!N?P#XWTFWU?0->NK.WN()T#/!,/%VO?9[VUEQ
MOM[NUD/F0SQ,LBG<`VUF!Y;0-9^*G_!*_P"//_".>(VU'Q/^SSX\OGELY86D
MN+-+&>;8MW$K%DLM<TO@WD*B.2\CA9HUD5\G]&O@C_P3YLO@#XRO_&G@#XR>
M,[6^UV5'\36MS;6D]GXBC6X>Z,>H)E69O.DDD1U=2KNQ(.:^M?CC\"_`7[0/
M@#4_A_\`$#3A>6%]!_HE_"$34=*OT`:"_L9V1S$\<RK(\8PLJ`QD@-FO'SKQ
M3X>J<8YK"I6GQ)X><68'*<'GF4U,+B,-B<!B,ORK`Y8LUP,<3&"I9A1GA?K%
M*I0FW5HQC2J.%6%.4?L>'?!;BJCP%D=2CAX<(^*O`^8YUCN',\I8W!XO!9GA
M<TSG'YN\ES*6$G4E6RS$4\8\+7I8F"5&O*=6DJE&I5C/L="^(/A+Q'X&M_B/
MHVL66H^$9]&?7EU6VN(I;86,-N;F;?*K%$EB1621&(*."K`$5^</[.O[/OPR
M_:@@^(G[1GQ:\-IXMG^)7CK6F\&S7MS<H+/P=H=[<:5I4<0BD3"S06T4JY&&
M5LK\N*Z/PU_P3J;P?X%UKX:>'/VA?B?IG@;7TDBU'P]%):M9O',,3)$74R0+
M,H"R+$ZJP`^4<Y^A?V=/V;-1_9WTK3_"ND_%#Q%XE\$:5!=0Z;X8UBTMO)L6
MN2S[K>YB971$D8R!&5LL3R!7P/UOASAG*N)/]4N,L3/-<?C<'3R_$0R_-,MQ
MBR##NMB:V$EB84^6EC<5B_J/M5&I'#SI865ZB<^2/Z<L#Q=QAG?"'^O7A_A(
M9+E>78^KFN&J9IDN;Y>^)\7'#82ACHX.=7GK9=@L`\R=!SI2Q=.MC8J-%NBY
MS_-3_@I%^R'\/OA+\(]`^,/P5\+Q^%M9\">)M/O-7NK.2XE"V?VB-[*[8S/(
M%D@U#R-C'```X[U^J_[+OQ6M?C7\!_AU\0;:02SZKH-K;ZF`V^6/5+"-;6\$
MZ\M'-))&9MCX;;(I`P03F?M(?L_2_M%>%3X'OO'>L^$_"E];-;Z_I>DVUO,-
M<`N4N8#/+/DQ"!HU"A%R>NX&O#/A)^PWJ_P/\/:AX4^'7Q_^(&B^'[\S2C3!
M#92V]E>S*B-?68D4F*?:@'4IT.S(S7=C>),FXJ\.LHRCB/B:I_K7DV=X[%8+
M%XW"YICF\FQ\*4:^"Q6,C1K3E5CB*:Q%#D]K"-**IWC)RMYV7<)9_P`%>*^>
MY[PGPA37`_$'#F78/,L#EV-R;+8_V_EDZDL-F.!R^>(H0C1EAJKPF)YXT:DZ
MSG549PA&4MWX57\&J?MQ_M*M;W%I,FE^!_`VEO%',LD[RFUTN6X+Q`G$<,FZ
M"0]`XVMS7Y??MA^'M6_8=_;-\'?M)>"[61/"'CB__MG4M/MLI;37$#1V_B72
MIHT_<)'<0&.>SAD"K).&D52P)'Z,?#O]@NZ^&7Q$UGXH^'?CQX^?Q=XE)7Q-
M?:A%:W0UV%YUN'BO8\QJ0)%#1F/9Y9`Q\HQ7T'^T?^S;X1_:7^'VF^!/&<\D
M0TO5M+UBTU>*%);I+BQ>(W2;69<1ZA$LL4JA@%\W=AMH%>ID_&?#7#7&.`K0
MS-YYPCFG"V7\)\4898#&8:I/!8?*,-@*]7V%>FO:6Q=%8JA*E*554G4IN-.<
MD>-G_A_Q?Q?P#F>'J9-'AOCO)N-,RXXX,QCS/+\92IYAB<\Q.9X:@L3AZDO9
M7P.(>"Q4:\(4?;QIU%*K"#OYE^QAH6K^)=*\9_M&^,;1X?%OQSUH:KIEO<C-
MUHG@.Q9U\.Z0!RL2O$RWCK%A7DD9CG-?GI^SXZC_`(*M_&12RAGOO%BHI(#,
MPCF)50>68*"2!D@`GI7[.^(/`5U-\/[3P)X'\1WO@$:;:Z9IVEZQI<$5Q=V&
MG:;%Y"VT4<NR,F6)8U:0C(*9P<FO@;0O^":.E^&_B9+\8=(^./Q!MOB-<:C>
M:K<^)2EFUW=7E^)%O'G4KY;I<1RR1R)M`V,=NTX-<G#/%G#TWXBXG.,UCE+X
MIX>Q'#N28"&`QN*6!P].6&CEL:LJ%.5.GA,-A<-1PON3J5KPE4=-[R[.+^!^
M*H+PHP>0Y)//%P7Q1A.+.(LSJ9GEN"EF>,JK$2SB=&GB:T*M3'8O&XK$8U.I
M"EA[5(TU525H?1O[:_Q.NOAC\`O$TND3O#XI\:2VO@/PH(@3.VL>)'^PHZ(`
M79(HI',C*,)E2W%<#\/?^">_[.FA>!_"6D^)_AY8ZKXDL-`TNWU_49;N\$E_
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MX;`P56<':"_"#XC>'=%_8*_X*$_#CQ+X4L7T7X6?$.#2[.:QC:5[9TUMO[+U
M*TW$LXMK'4KBVN&).$$;,QV@FOW5^*$D<_PP\:SP.LL,WA+5IHI4(:.2*73Y
M721&'#(RD%6!P1S7QS^T9^P+I'[37BZW\3^/OBCXI6'1Y[MO"^D6-M;16_AZ
MUNI$E:VMI<F20K*@D$KD,&Y`&!7HTG[,7C-_A?%\+6^/OC=],5;FRFU66ULW
MU6;1)K.VLX-'\_(`AM1#(\<A5G8S,&/%?0\49]PSQ3@N`,QQ7$:_UGR?`8;*
M^)<17R_,ZD<5A\)B'6P6)5=8>4\1BJ%%SHXER2]K5G'DG*G#F7RW!?#/&'!6
M8>*&58+A-_ZFY_F>+SGA#"X7-,FI3P6+QV$CALQPCPSQ4*>%P.(KQIXC!QC)
M^QHTYJI3C5GR'PG_`,$5&4_#3XX1AE\S_A/M'?9D;]@TV[4OM^]M#$+NQC)`
MSDU^N'Q-^*'@SX.^#M:\>^.]9L]%T/0;.:\E>ZF2.:[EA0O#8V<!/FW-U<R!
M8HXH4=LODC`)KX$^%G_!-RV^"=U?7?PN^/GQ(\(/J>W^TH]-%C]GO]ARGVF&
M6.17*GD%=K=MVTD'V"+]AOX?>(M1L=9^,GC+XA_&N^L)!+#8^-->C/AO>LGF
M(QT.QL[9&V$)LWW#$;>3VK/CS&\!\4<=9OQ5+B7%U<GS+$X7$U,MP>38N.;R
MC1P>&PU7#4YXQT,!2=1X=\N(G7G[-5%)T)N#@]/#'+?$O@SPUR+@J'".!HY]
ME&$QF%IYMF&?X&>10GB,=B<72Q56E@%B<SK*C'%+GPL,-3]K*E*/UFDI*2^#
M/^">GPK\5_&']H[XD?ME>*=)O-.\,ZA?:U;>`SJ43Q3ZD=3F96>&&7YY;>RL
M%@1+I5\L2[HU?=D5]0>+_!7A']K']K_7?"OB^QC\1_#CX`^$!975DL[K:S^.
MM>>"66WNC`ZDS6$#7*?.=RD;5XS7W9XA\#?:?`\O@KP1JC?#R-((K73;[0+2
M!6TJWC!5H[2W.V-2Z$#><L,;CN-?)?P;_8FU#X(>+-=\6^%/C?XSNKSQ=J\&
MK^,8-7M;6]C\17,4PDDDNFW(Z32INA$BG"*Q^1L"M<3QW@<]S+B#BBIFD>',
MTH9#1X;X*RVE0S"N\KR^G[##NH\?AJ,E3Q']G/&485H6E+%8NI4<:-.,6983
MPUS'AK*.%^#:.33XMR;$\35N+?$/.,1B<KP\<YS2M[;$JE'+,;7C*MA?[56`
MKSH3?+'!8&E34ZU:52)R?Q^_X)Z_`C7/@[\0++X?^`;'1O&B^'-1N_#FHQW-
MT[6^HV=N]Q&VV:9XR"L;#!!R2`,FO._^"27QDG\9?!76OA5K<\I\0_"S5VMK
M>"Z8F\?0[UFVLR-^\2&RN%2TC1P`F=J@"OTO^('AC6/%_AB^T'0_%-]X.O;T
M>6=;T^"*XNHH&1DFBCCF(0>:C%2QSCTKX'^%?_!.33_@UXVN_'O@/XV>/-'U
MO59-VO&&*S^SZY`UR+J6UOX=NPQ23#?^[V,I/!QQ6&6<79?GGA_Q)PUQGQ)B
MJN8U<RP&:\,U\;2S/,ZV#QF%C.EBX5L0H5O9X3&8::I1A3G.4*CJ3G32DI+H
MSC@7-.'/%'A+B[P^X1P5'*:&49EDG&&'RZME&3X?'X#&SIU<#/#X5U*'M<=E
M^+@Z]2=6$(SHJG3IU7RN+_2VBF1JR11([F1TCC1Y",&1U15:0@<`NP+D=B<4
M^OQG\3^@5Z6\CVBBBB@#S'Q#_P`AB\_[=_\`TE@KQ'XW_"_2_C3\)?'WPMUE
M8VLO&7AV_P!)5I03%!>RP/\`8+MP.2+6Z\N;CGY:]N\0_P#(8O/^W?\`])8*
MQ:WPN*KX+%8?&8:I*EB<)7HXG#U8Z2IUZ%2-6E4CYPG&,EYHY\7A</CL+B<%
MBZ4:V%QF'K87$TI?#5H5Z<J56G+RG3G*+]3_`#M?B'\./$7PB^)/BCX;>*[2
M>RUWP?KM]HMW'<1M&\R6=R\-O>*&`S'>P)'<QD9&V45^EW[&4B_"_P"#_P`=
M_P!H"X5XK^P\/-\,?`TZC9.OB7Q=:_9+^YLY&QE[/2M1\YC&=R[#GV_7?_@J
M)_P3B?\`:(MF^.7PBM(8/BUX<LC_`&]H42+&GCG2K:,G$8&T?VW:JH:!L@W2
M@QMN(05^-?P0;X;:AX*G^"?[0GQ4^(GPA@\+>*+O58_#=CX-L[NR_M9XQ!/-
MJHN+=M3-_'M,21S1B-(579QBO]%<#X@Y;XF<!87%4)SEBZ=?+*7%V4X3#8G&
M9A0I4J].MC88?!82C6Q%?#9@Z*I4JL*?L_JU>K&<E4I3IG^:N.\.,U\+?$'&
MX3$0A'!U,+FM7@W.,9BL+@<NQ%6MAZE'!5,1C\96HX;#XO+%7=6K1G4]I]9P
M]*<(NE5A4'?`3QWJ'P\^)_@OQW;7#)=Z)K]G?W%P6*L\4L@2^9F'.Z2&64D\
MY)YZU^W/[>-AX=L?A=\!YO"J*FAZWKGB/Q/:!=F"WB>S?79SF/Y23-?.21R2
M>>:_./1/A-^P[&T9MOVHO'$YR,!_`,29XXY^Q\=/SKZKN)/V>_%_AOPMX3UK
M]J7QQKFA>#Q(OAVSN_!L8%BLL7DL%<6FY@(L1J&/RH`H&!7R'%-?!YGQ/PMQ
M'AL)Q'0_L6IC(8^C4X6XAI_6L-5P>(I83D7]G<KJ86OB:TH*7*HT\16L[M1?
M9PYA\?E/!O''"F+QW"E?_6.G@)Y97AQEPK)8+%T,PP.(QKJ.6;*4:6,PV"HJ
MHZ:E*53"X=2BXKFC\[^$_$EYX/\`$VA>*-/+"\T'5++5(54E?,:RN([CRB?[
MLOE[&'0@\U[#^TIH=G8?$5_$>E(BZ)X]TNS\7Z;Y*;;=#J2;KR!"/E+1W7F[
MPIXR,]:Z8_#W]E<`G_A?'BH^W_")1\_^2M<KXBTQ_B+KWA'X=?##6?$WQ"LM
M&MGT_2)=5TJ"SDLH9I%,BQFV4%;"/&]GN2H0G@@G!W6987%YSA,SHTLQP-/"
M8+'4,SK9GE68Y;AY8&4:>(I3>)QF&HT.?#XBBG%2G']W6KV=[)_*2R?'8'AW
M'Y)B*V49G5S#,\KQ628;)<]R?.<9'-(2J82O".$R[&XC$NGC,'BG&<H4Y7K8
M;#)QY;SC'^S?\*[WXL?%3P[HB0%](T^\AUC7YF4F"/3+"07$T+M@J'NA'Y$2
MGEG85^[/Q'^(WA7X->"KCQCXL75U\-:*+*SN7T72IM8O($D:.TMF-G`Z.8]V
MQ&<-A<],5YA^S5\`],^!G@\6DS17OBW60ESXAU0+N(D(#IIULV/DM;7Y4(7B
M62,RDDL:H?ME"XN_V>/'.DV%AK.JZCK"Z=965CH.GWNH:C(XOH9I7BBL8)Y8
MO*A1Y!,4"JR@9W$`_P`W\9\38/C_`(\R?`0E4GP]A\?A<LHSIS]C.M1Q.*I1
MQ^.A.<)JESI7I2G3?+1HPG-*\DO[*\->"<?X5>&&?9I5ITJ?%F,RW&9UB:=6
M#Q%/#5L)@ZL\KRRI"G.$JKI2;]O"G43EB,34I4Y/EC*7HGB;XX>"/"/_``KT
M:S%XG1OB?>6]AX32T\.W-T\UU<VPNX8]1"2K_9VZ%@V92^#D$9%=EX8\76OB
M:SU"].FZMH":?K>IZ(8O$5JNERW,FFW+6WVVT664B6QO"OFVDVX&6(AMHSBO
MSR\>_#^S\,:K^RMXCL-5^,GB2WMO$6G7VMV^LWGBCQ+::%I\>BK'<W,FF_89
M'TF6&1S'%YJ1RJ1M13M->)^*?$7CH66F>%O-\>ZE)J/Q)_:`:VLM<MO%/VBW
M\-ZK=Z_)X*\3/;VEH=9NH].MY;2;2I5@-I!)%#"[)*NRN3#<!9;F>%P;R[&U
M85*RQ4\1B<5!KD6&Q6;QE&EAN:$4XT,!0A/VM;WZM>$XNFI*F_6Q7B=F^3XW
M'K-<NH5*5#ZE#"83!U4W4EC<%D$H3K8ODG*2GB<TQ%6"HT%[.CAZE*I&K*#J
M1_4NV^+NC7'Q=U+X0&QN(=4TWPO8^*GU:6:!=-GM;^>XMX;>!BV7G#6TA8`\
M`IC.<5M?$/XG>%/AE8:;>>)9KY[C6]2AT?0M'TBRDU/6]:U*?[MMIVGQ,LD_
MEK^\N)`P2"+,C\"OR(M-#T_Q5J.H>)_#VI?%/Q)9:1\#]$M],\76]CXKM[S4
MO%NE:W=B_MGD%BLMW<6TFU8[0@N(RQ\LY:OL7XN^'_'-[/\`LO\`QOTK1]7\
M60_#-OM/C;PTMO*FLK9>(_#R:;?ZY;Z?.J7,^HZ9,[336RPM<L`5CC+X%1F'
M!63X+,\HP]3&U*5&OA:]#%T*Z>!J5<WPN5SQ=&BJN*G46%_M3&*EA.2M3IO!
M3J<C4I+37*_$3/<PRC/<53RZG5KX;&87$X#$89K,:5'(\;G-+`XG$.A@Z=)X
M[^Q<!*MCE4P]6HLPITN=.$=_H[P1\<?"/C+Q1J7@6:WUOPIXWTRT34Y/#7BK
M37TF\O-)F_U.I:8\CF*_MOX9S$0UO(#&XR":]B\V,E@)(\J`SC>F54]&89RJ
MGU8`>]?E_P#$'7M+_:?^*>N^*/A+=:C#=_!/X2_$'2=1N#'>^'?&-UXQUG1K
M^XT/1;;2+R.UUDQ6=X]NWVF:T^S-=*@@=P17#CQ?\2VUO6];M/#GQ<N-+O\`
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M],E\^.YN@D,OE)A]R%1MF'`&`P="49Y@H3PN'KNIBZ$%B?KU:A4XHKJ5##O%
M1A%5<'E>7QG!56X3KT9PYUB+O#*_$_,\?B8RI96ZD,;BL,J.!Q-1X3^SJ&)I
M<%X9PQ.*6#E4G*EF&=9K*G4E12J0PU>%14_JON_JS+<PQ122[Q((HWE*0E99
M66-2S;$5LLV`<`=3Q7S!9?MA?![4FDCLSXPBE?4_%GA_3I=7\*WFDZ;JOB;P
M9!?3:QX=M-2FF>$ZD/[/N$MXF4"8A2I&ZO/_`-E70_',#^.M5\;ZS?:MIW@F
MZUGP)X4O?[0FU!/$VGVNH7=__P`)+<",R17.H+;O%I4Q7,@D@(*AL@^-?!?X
M5Z5XH\#_`!)\4>,=.\;Q:IX!^)_QM\8^#/#U_INL:=ILUQXM?6QI&O6NE36D
M<FK74]A>,8-B2M%*Z$*'`!X<'POD&$J9]3S;&5\PCE=;*L/0Q&5SC3A4JYG1
MQCI1]E4A4=2/MXX"-9NI2^KQJUH3_>QB>ECN,N*,?2X9K9)E^&RN6<T,YQ.)
MPF<TY5:E.AD]?+E7E[:E4I1IR^K3S.=!*E76)G1P]2#]A*;?Z'?#/Q]I_P`3
M/!&@^-M/M9=.@UZUFNDTVZEB>]LUANI[5DN5C)VMNMV;.`.<9X-=P+BW*[Q<
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M5HNC&G6C'G/VF\^W)`$\&6P%'G19.[E<#=SN`)&.N.*//@V&3SX?+4[6D\V/
MRU;.-K2;MBG/&"P(/!YK\=/BKX,\0:7X@^,FG^&M3^.#+HVO?!6P^&,]E<>+
M;H2V$.JZ:GC><7BV3QSFWT6:_P#.NI&/.50LXP-[4[[Q1I7ASXC^#]'T?XL:
MOI%[\5=>G\+17Z>+E?\`X1VX\(:"EA<7&J)9"]FADUY-2>TA)$23B8W&Q&0G
MECX<TJM#"5L/GD:GUGZO-PJ8%4'3HUL+EF*E-RJ8WD<J<<S5+D;BG7PF-IN<
M?8IS]"?BQ5H8C&T,5PY.E]4>)IJ=+,98E5,10QN;X*$%&EEW/[.K/)ZE?VD8
MRE'#8[+JJIR6(:A^MK3P)LWSPQ^80(M\T:>83T$>YAYA/8)DGM0;BW!=3<6X
M:/!D4SQ!HP>GF*7W)GMN`S7Y/_##4_&.J67P]T/XT>$OC%J$<OPP\'Z5X8OM
M.75K26Q\;:,MA_;D^K7$$0DM-1N-2@<G4=1\N.;3VFA#LLV3SGAWPE\8?$6D
M?%&+7]3^*T/Q)T[2?&Z?V+_8YT[2;E&GBFT2>W\3HJC6)H;&WMETY()9)8KC
M[6`"92##\.J=*IB:>)X@P=%86=&,JRHJM1K0KUYT(U\/.CB9R='#SINECJE>
M&'AA<1*E2<YJHI*H^*]6M2P=7"\+9AB'C:=><<.Z\J&(PU3#8:EB)8?%0KX.
M$8XC%4ZT:V74L//$U,9AH5JRA3=-P?Z_7%]8VD4L]U>6MM#"H::6:XBC2)2<
M!G9G`4$\`GKVS6#I_BNSU'Q%K7AV&SU%&T2RTZ^EU>6W5=$O8M2@$\::?J`D
M:.YD@0XNE`40MP2>M?DAJ-MXU\<:;\0_[0TWXKW&F3?#SX6NEO)9>)+&XO=<
MT:[E'B06$;6D<OVE%(^T*@+7!PZ!P178Z[=?$'P_X@^(*?#C2/B=J'@(>'O@
M_>-I-Q;:Z-2D\.VD>G0^,K31KJ_MXY%U!)G(O;2W+7=S;K.BQE"Y&R\.J454
MH2SBA+&2IPLZE.-#"4)SGDCM*N\2[XCES.O3C0J0IPE]6JR=6$H2C'GEXKUY
M^RQ,,@Q$,#&K4NJ5:>)QN)IPI\0ZQPZP24<+?*,/5GB:52I5I_7*$%0JQJQ<
MOUA^T6^Q9/M%OY;L%67SXO*9CT59-^PM_L@EO:O//"'Q)T_Q9XE^)7AE;"ZT
MJY^&>MZ/HNI7-^\4<%\^M:;+J=K<VS$@)#Y,17]X068\>E?F)\=;GQ)/X/;2
M?@]X+^,]E::KIEQK^A2ZM<^)6-KK?VRUWKIUE'`TEI<1+;2".UU58(4RSP[A
M*<[GB[4_%NM'XQWNE)XWT"_\1>*OAEXCAN)O!OB.?3]8M-$\(3V.IV>K06^G
M-<36K:DRVKK9!YHY6$P'E`M3POAY2E@U6K9A!3QJG2P_M*:C7RZI1S3)J$JN
M*PV%Q.*YW7PN,QT%1;4H5,-4DN;DYDL9XJUH8_V%'*JG)E\H5<4J55SPV;4L
M3DN?8F%'!XS&8/!JE]6QN!RVHZZCRU:6,I0ERNHHO]9E974,C*ZL,JRD,K`]
M"K`D$'L0<&EKR+X`W.KWGP3^&-UK^CWV@:U/X5MI-2T74IKFXOM.N3=W@,-Q
M->`7;%HQ'-&+D":.&6.)P"F*]=K\TQN&>#QN,P;G&H\)B\3A74BXN-1X>M.B
MYQ<)U(.,W#FBX3G!IIQG*-I/]>R[%K,,OP&/5.5)8[!83&JE-34Z2Q6'IUU3
MFJD*512@JG+)5*=.:::G3A*\5[11117,=AYWKME>S:K=216=U+&WD;9([>5T
M;%M"IPRH5.&!!P>""#R*QFTW4^,6%]W_`.72?_XW7KM%`'E%GIUTLX:ZTS4'
MBP>!:7'W^-I/R#(ZY&1UZU\'?M3_`+`/P\_:(N+C7KCPFFC^+VC98?$^AV36
M&HNRC]R+Z/R#'=C=@RDA97&1YH/-?J117IY1G6;9#C:>89-F&*RW&TOAQ&%J
MRI3M=-PGROEJ4Y6]ZG44J<E\46>7G&291Q!@JF6YWEV$S/`U?BP^+HPJP4K6
M52#DN:E5BFU&K2E"I&[M)7/Y7M?_`."47[1/A>\8^%8+7Q38(Y*/-!<Z;<B,
M?=41!+L2-C'.Y<FMO0/V`_VG[,QI<>`+A#D9;-SL'0<G['P/4^GK7]0U%?K-
M/Q]X]^KQHXF>4XR<5;ZQ6P')6GMK-8>M1HMZ+X:4%Y'X;B_HR>&>(Q%2M0AG
M>`A4ES?5L-F?/0A?=4WBL/B*Z5ME.M.W330_`3P=_P`$]_BQ?W$+^+;:72K4
M,IF@M+>::9UR-RI,R(L9QG#-&XSU6OT[^!_P#T3X.Z6;33?#212SJGVR]:QE
MNM5NV5<9DNO)4IG))6/8IXRF1S]@45\+Q%Q]Q3Q1%TLUS*;PC:?U'#0CAL'H
MTUSTJ=G6LU=>WG5:>S1^@\(>%/`W`\U7R+)::QZ3C_:F-G/&YA9JS]G7K7CA
M^9:26%IT%)?$F>/3:?J!ED,.E:@L1=BBM:W!(7)V@_NO3%,&GZJ#D:;J`/M:
M7'_QJO9**^-/T4\;_L_51G&FZASU_P!$N/\`XU7"^*_A)X>\;:CINK^)?"=[
MJ&IZ/;W-KIM^HU2TNK6VO%=;F!)K1H7,4HD<E&)`8[A@@5]/45M0Q&(PM15L
M-6JX>LHSBJM"I.E449Q<)Q4X.,E&<6XR5[2BVG=,PQ.&PV-I/#XS#T<50<H3
M='$TH5Z3G3FJE.;IU(RAS4ZD8SA*UXS2E%II,\#T'P@GA?2++0M`\/7.F:3I
M\9CL[*WM+D1PJS,[8+1EV9G9F9W9F8DY)K7_`+.U3K_9M_GKG[)<?_&J]EHK
M.<YU)RJ5)2J5)R<YSG)RG.<G>4I2DW*4I-MN3;;;NW<TIPA1ITZ-&$:5*E"-
M.E2IQ4*=.$$HPA3A%*,(QBE&,8I**225CY4/P3\&_P#"P8?BHG@1K?Q_#;?9
M#XBM;>_M;FXM]C1[+V&`1VU\0CD*]U%*P."#D#'H_P#9^J_]`[4/_`6Y_P#C
M5>R45K7Q6)Q7L?K.(KXCZO1AAZ'MZLZOL</2;=.A2YY2]G1IN4G"G"T(N3Y4
MKLRPV#PF"]O]3PN'PGUK$3Q>)^K4*=#ZQBJJBJN)K^RC'VN(J*$54K5.:I-1
MCS2=D>.?8-6/73M1_P#`6Y_^-55O-%O[ZSN[&?3=2\B^M9[2XV6]U&YAN8FA
ME"2+&&1MCMM=3N4X(Y%>VT5BFTU):.+336Z::::?1II->:.B7O)QE[T9)QDG
MJFFK--/=-:-'SOX3\!6G@?0+#PSX9\/7FFZ-IRN+6U6WNY-K2L9)I'DDC:22
M6:0M)([L2SL3WKI/[/U4]=-U`_\`;K<?_&J]DHJZM6K7J5*U:I.K5JSE4JU:
MDI3J5*DVY3G.<FY2G*3<I2;;;;;=S.C1I8:C2P^'IPH4*%.%*C1I0C3I4J5*
M*C3ITX02C"$(I1A&*2BDDDDCQO\`L_5?^@;J'_@+<_\`QJC^S]5_Z!VH?^`M
MS_\`&J]DHK.WE^']=E]QKS/N_O/&_P"S]5_Z!NH?^`MS_P#&J/[/U7_H&ZA_
MX"W/_P`:KV2BCY?U_207?=GC?]GZK_T#=0_\!;C_`.-4?V?JO_0-U#_P%N/_
M`(U7LE%`7?=GC?\`9^J_]`W4/_`6Y_\`C5']GZK_`-`W4/\`P%N?_C5>R44!
M=]V>-_V?JO\`T#=0_P#`6Y_^-4?8-5_Z!VH?^`MS_P#&J]DHHMY?A_79?<',
M^[^\\C73M2*C.GWP..0;6?/_`*+I?[-U'_GPO?\`P%G_`/C=>MT4""BBB@#_
!V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
